Skip to main content
Erschienen in: Supportive Care in Cancer 4/2012

01.04.2012 | Original Article

EORTC QLQ-C15-PAL quality of life scores in patients with advanced cancer referred for palliative radiotherapy

verfasst von: Amanda Caissie, Shaelyn Culleton, Janet Nguyen, Liying Zhang, Liang Zeng, Lori Holden, Kristopher Dennis, Esther Chan, Florencia Jon, May Tsao, Cyril Danjoux, Arjun Sahgal, Elizabeth Barnes, Kaitlin Koo, Edward Chow

Erschienen in: Supportive Care in Cancer | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Symptom control and improved quality of life (QOL) are primary goals of treatment in palliative oncology. The present study assessed and compared patient demographics, baseline Karnofsky Performance Status (KPS) and QOL using the QLQ-C15-PAL questionnaire prior to palliative radiotherapy (RT) for bone, brain, or lung disease. Few studies have used this questionnaire, an abbreviated version that was developed by the European Organization for Research and Treatment of Cancer specifically for patients with advanced cancer to decrease the burden of completing the longer, more time-consuming QLQ-C30.

Methods

Patients referred to an outpatient palliative RT clinic completed QLQ-C15-PAL questionnaires prior to palliative RT for bone, brain, or lung cancer sites. The associations between baseline QLQ-C15-PAL functional/symptom scales, patient demographics, and clinical variables including KPS were explored.

Results

When data from all 369 patients were analyzed, higher KPS scores correlated significantly with better overall QOL and higher physical and emotional functioning. The QLQ-C15-PAL provided more detailed information regarding how symptom burden varied depending on disease site. Patients with bone metastases had worse QLQ-C15-PAL scores for pain, while those with brain and lung disease had worse scores for fatigue. Other health-related QOL scores measured by the QLQ-C15-PAL varied as a function of age and gender.

Conclusion

As the QLQ-C15-PAL provides detailed and often critical information regarding symptom burden, it may eventually be recognized as a universal core questionnaire to assess QOL in this patient population with advanced cancer while relieving the survey burden.
Literatur
1.
Zurück zum Zitat Kirkbride P, Tannock IF (2008) Trials in palliative treatment—have the goal posts been moved? Lancet Oncol 9:186–187PubMedCrossRef Kirkbride P, Tannock IF (2008) Trials in palliative treatment—have the goal posts been moved? Lancet Oncol 9:186–187PubMedCrossRef
2.
Zurück zum Zitat Movsas B (2003) Quality of life in oncology trials: a clinical guide. Semin Radiat Oncol 13:235–247PubMedCrossRef Movsas B (2003) Quality of life in oncology trials: a clinical guide. Semin Radiat Oncol 13:235–247PubMedCrossRef
3.
Zurück zum Zitat Spilker B, Revicki A (1996) Taxonomy of quality of life. In: Spilker B (ed) Quality of life and pharmacoeconomics in clinical trials. Lippincott Williams & Wilkins, Philadelphia, p 1259 Spilker B, Revicki A (1996) Taxonomy of quality of life. In: Spilker B (ed) Quality of life and pharmacoeconomics in clinical trials. Lippincott Williams & Wilkins, Philadelphia, p 1259
4.
Zurück zum Zitat Chow E, Wu JS, Hoskin P et al (2002) International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiother Oncol 67:275–280CrossRef Chow E, Wu JS, Hoskin P et al (2002) International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiother Oncol 67:275–280CrossRef
5.
Zurück zum Zitat Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376PubMedCrossRef Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376PubMedCrossRef
7.
Zurück zum Zitat Wong J, Hird A, Kirou-Mauro A, Napolskikh J, Chow E (2008) Quality of life in brain metastases radiation trials: a literature review. Curr Oncol 15:25–45PubMedCrossRef Wong J, Hird A, Kirou-Mauro A, Napolskikh J, Chow E (2008) Quality of life in brain metastases radiation trials: a literature review. Curr Oncol 15:25–45PubMedCrossRef
8.
Zurück zum Zitat Yaneva MP, Semerdjieva MA (2006) Assessment of the effect of palliative radiotherapy for cancer patients with intercranial metastases using EORTC-QOL-C30 questionnaire. Folia Med 48:23–29 Yaneva MP, Semerdjieva MA (2006) Assessment of the effect of palliative radiotherapy for cancer patients with intercranial metastases using EORTC-QOL-C30 questionnaire. Folia Med 48:23–29
9.
Zurück zum Zitat Roos DE, Wirth A, Burmeister BH et al (2006) Whole brain irradiation following surgery or radiosurgery for soliatary brain metastases: mature results of a prematurely closed randomized trans-Tasman radiation oncology group trial (TROG98.05). Radiother Oncol 80:318–322PubMedCrossRef Roos DE, Wirth A, Burmeister BH et al (2006) Whole brain irradiation following surgery or radiosurgery for soliatary brain metastases: mature results of a prematurely closed randomized trans-Tasman radiation oncology group trial (TROG98.05). Radiother Oncol 80:318–322PubMedCrossRef
10.
Zurück zum Zitat Gerrard GE, Prestwich RJ, Edwards A et al (2003) Investigating the palliative efficacy of whole-brain radiotherapy for patients with multiple-brain metastases and poor prognostic features. Clin Oncol 15:422–428CrossRef Gerrard GE, Prestwich RJ, Edwards A et al (2003) Investigating the palliative efficacy of whole-brain radiotherapy for patients with multiple-brain metastases and poor prognostic features. Clin Oncol 15:422–428CrossRef
11.
Zurück zum Zitat Mauer ME, Taphoorn MJ, Bottomley A et al (2007) Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study. J Clin Oncol 25:5731–5737PubMedCrossRef Mauer ME, Taphoorn MJ, Bottomley A et al (2007) Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study. J Clin Oncol 25:5731–5737PubMedCrossRef
12.
Zurück zum Zitat Kramer JA, Curran D, Piccart M et al (2000) Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Eur J Cancer 36:1498–1506PubMedCrossRef Kramer JA, Curran D, Piccart M et al (2000) Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Eur J Cancer 36:1498–1506PubMedCrossRef
13.
Zurück zum Zitat Groenvold M, Petersen MA, Aaronson NK et al (2006) The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer 42:55–64PubMedCrossRef Groenvold M, Petersen MA, Aaronson NK et al (2006) The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer 42:55–64PubMedCrossRef
14.
Zurück zum Zitat Steinmann D, Schäfer C, van Oorschot B et al (2009) Effects of radiotherapy for brain metastases on quality of life (QoL) prospective pilot study of the DEGRO QoL Working Party. Strahlenther Onkol 185:190–197PubMedCrossRef Steinmann D, Schäfer C, van Oorschot B et al (2009) Effects of radiotherapy for brain metastases on quality of life (QoL) prospective pilot study of the DEGRO QoL Working Party. Strahlenther Onkol 185:190–197PubMedCrossRef
15.
Zurück zum Zitat Suárez-Del-Real Y, Allende-Pérez S, Alférez-Mancera A, et al. (2011) Validation of the Mexican–Spanish version of the EORTC QLQ-C15-PAL questionnaire for the evaluation of health-related quality of life in patients on palliative care. Psychooncology (in press) Suárez-Del-Real Y, Allende-Pérez S, Alférez-Mancera A, et al. (2011) Validation of the Mexican–Spanish version of the EORTC QLQ-C15-PAL questionnaire for the evaluation of health-related quality of life in patients on palliative care. Psychooncology (in press)
16.
Zurück zum Zitat Fayers PM, Aaronson N, Bjordal K et al (2001) The EORTC QLQ-C30 scoring manual, 3rd edn. European Organization for Research and Treatment of Cancer, Brussels Fayers PM, Aaronson N, Bjordal K et al (2001) The EORTC QLQ-C30 scoring manual, 3rd edn. European Organization for Research and Treatment of Cancer, Brussels
17.
Zurück zum Zitat Shapiro SS, Wilk MB (1965) An analysis of variance test for normality (complete samples). Biometrika 52(3–4):591–611 Shapiro SS, Wilk MB (1965) An analysis of variance test for normality (complete samples). Biometrika 52(3–4):591–611
18.
Zurück zum Zitat Echteld MA, Deliens L, Onwuteaka-Philipsen B, Klein M, van der Wal G (2006) EORTC QLQ-C15-PAL: the new standard in the assessment of health-related quality of life in advaced cancer? Palliat Med 20:1–2PubMedCrossRef Echteld MA, Deliens L, Onwuteaka-Philipsen B, Klein M, van der Wal G (2006) EORTC QLQ-C15-PAL: the new standard in the assessment of health-related quality of life in advaced cancer? Palliat Med 20:1–2PubMedCrossRef
19.
Zurück zum Zitat Groenvold M, Petersen MA, Aaronson NK et al (2006) EORTC QLQ-C15-PAL: the new standard in the assessment of health-related quality of life in advanced cancer? Palliat Med 20:59–61PubMedCrossRef Groenvold M, Petersen MA, Aaronson NK et al (2006) EORTC QLQ-C15-PAL: the new standard in the assessment of health-related quality of life in advanced cancer? Palliat Med 20:59–61PubMedCrossRef
20.
Zurück zum Zitat Chow E, Bottomley A (2009) Understanding the EORTC QLQ-BM22, the module for patients with bone metastases. Expert Rev Pharmacoecon Outcomes Res 9:461–465PubMedCrossRef Chow E, Bottomley A (2009) Understanding the EORTC QLQ-BM22, the module for patients with bone metastases. Expert Rev Pharmacoecon Outcomes Res 9:461–465PubMedCrossRef
21.
Zurück zum Zitat Chow E, Hird A, Velikova G et al (2009) The European organization for research and treatment of cancer quality of life questionnaire for patients with bonemetastases: the EORTC QLQ-BM22. Eur J Cancer 45:1146–1152PubMedCrossRef Chow E, Hird A, Velikova G et al (2009) The European organization for research and treatment of cancer quality of life questionnaire for patients with bonemetastases: the EORTC QLQ-BM22. Eur J Cancer 45:1146–1152PubMedCrossRef
22.
Zurück zum Zitat Rosemann T, Hermann K, Miksch A, Engeser P, Szecsenui J (2007) The PAMINO-project: evaluating a primary care-based educational program to improve the quality of life of palliative patients. BMC Palliat Care 6:5PubMedCrossRef Rosemann T, Hermann K, Miksch A, Engeser P, Szecsenui J (2007) The PAMINO-project: evaluating a primary care-based educational program to improve the quality of life of palliative patients. BMC Palliat Care 6:5PubMedCrossRef
23.
Zurück zum Zitat Cheung WY, Le LW, Gaglieses L, Zimmermann C (2011) Age and gender differences in symptom intensity and symptom clusters amoung patients with metastatic cancer. Support Care Cancer 19:417–423PubMedCrossRef Cheung WY, Le LW, Gaglieses L, Zimmermann C (2011) Age and gender differences in symptom intensity and symptom clusters amoung patients with metastatic cancer. Support Care Cancer 19:417–423PubMedCrossRef
Metadaten
Titel
EORTC QLQ-C15-PAL quality of life scores in patients with advanced cancer referred for palliative radiotherapy
verfasst von
Amanda Caissie
Shaelyn Culleton
Janet Nguyen
Liying Zhang
Liang Zeng
Lori Holden
Kristopher Dennis
Esther Chan
Florencia Jon
May Tsao
Cyril Danjoux
Arjun Sahgal
Elizabeth Barnes
Kaitlin Koo
Edward Chow
Publikationsdatum
01.04.2012
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 4/2012
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-011-1160-6

Weitere Artikel der Ausgabe 4/2012

Supportive Care in Cancer 4/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.